Coya Therapeutics Inc — Cash Flow (NASDAQ:COYA)

Financials

Cash from operating activities -7.24 M-11.19 M-10.29 M -12.14 M Cash from investing activities -525 K-543.19 K-25 K — Cash from financing activities 9.36 M38.43 M16.03 M 9.73 M Free cash flow -7.24 M-11.19 M-10.29 M -12.14 M

新闻

H.C. Wainwright 维持Coya Therapeutics股票买入评级，目标价18美元

H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock with $18 target

Coya Therapeutics完成1110万美元私募融资

Coya Therapeutics secures $11.1 million in private placement

Coya Therapeutics推进ALS和FTD临床试验至2026年

Coya Therapeutics advances ALS and FTD clinical trials in 2026

H.C. Wainwright维持Coya Therapeutics股票18美元的买入评级

H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18

Tracking David Einhorn’s Greenlight Capital Portfolio – Q3 2025 Update (NYSE:GRBK)

H.C. Wainwright重申Coya Therapeutics股票买入评级

H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock

H.C. Wainwright重申Coya Therapeutics股票买入评级，目标价18美元